Drug Type Small molecule drug |
Synonyms Pazufloxacin, Pazufloxacin Mesilate Sodium Chloride, Pazufloxacin Mesilate and Sodium Chloride + [36] |
Mechanism Bacterial DNA gyrase inhibitors, Topoisomerase IV inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (11 Apr 2002), |
Regulation- |
Molecular FormulaC17H19FN2O7S |
InChIKeyUDHGFPATQWQARM-FJXQXJEOSA-N |
CAS Registry163680-77-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Pazufloxacin Mesilate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Infectious Diseases | CN | 01 Jan 2004 | |
Bacterial Infections | JP | 11 Apr 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic purulent otitis media | Phase 1 | CN | 27 Jul 2018 |
Phase 3 | 46 | (PRO-157) | jwajkhlccx(ewfohmzyhc) = wtttfbomuu ilaamuqitt (vmkexiiqkc, olxxkybpvt - kblfhwsiam) View more | - | 24 Aug 2021 | ||
(Zymar) | jwajkhlccx(ewfohmzyhc) = pqxjqpyshl ilaamuqitt (vmkexiiqkc, uaasokqsgx - tnxvoimzpw) View more | ||||||
Phase 2 | 150 | (PRO-157 BID (2 Times Per Day)) | vcnlhawlug(wuatknkxhw) = jqzyqgkmjg rfwsrnnmni (rmasisyomw, pclxutxpal - eiegfqdlvu) View more | - | 15 Feb 2019 | ||
(PRO-157 TID (3 Times Per Day)) | vcnlhawlug(wuatknkxhw) = buxsxddocg rfwsrnnmni (rmasisyomw, apkszthqnh - enktntohbw) View more |